BSE Live
Apr 10, 16:01Prev. Close
58.25
Open Price
60.57
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:41Prev. Close
58.23
Open Price
59.90
Bid Price (Qty.)
58.05 (786)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Lyka Labs (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -19.48 | 0.58 | -4.24 | -0.13 | 2.17 | |
| Diluted EPS (Rs.) | -19.48 | 0.58 | -4.24 | -0.13 | 2.17 | |
| Cash EPS (Rs.) | -16.60 | 2.19 | -1.61 | 2.42 | 3.38 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 6.55 | 35.04 | 34.39 | 33.40 | 28.49 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 6.55 | 35.04 | 34.39 | 33.40 | 29.68 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 14.20 | 14.63 | 14.81 | 35.39 | 25.98 | |
| PBDIT/Share (Rs.) | -0.22 | 1.28 | 0.49 | 10.65 | 8.70 | |
| PBIT/Share (Rs.) | -2.92 | -0.30 | -1.75 | 8.14 | 7.50 | |
| PBT/Share (Rs.) | -19.22 | -2.52 | -3.99 | -0.25 | 2.58 | |
| Net Profit/Share (Rs.) | -19.31 | 0.62 | -3.85 | -0.08 | 2.19 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -1.52 | 8.73 | 3.29 | 30.09 | 33.48 | |
| PBIT Margin (%) | -20.58 | -2.04 | -11.83 | 23.00 | 28.87 | |
| PBT Margin (%) | -135.36 | -17.24 | -26.92 | -0.71 | 9.94 | |
| Net Profit Margin (%) | -135.93 | 4.20 | -26.00 | -0.23 | 8.41 | |
| Return on Networth / Equity (%) | -294.93 | 1.75 | -11.19 | -0.25 | 7.67 | |
| Return on Capital Employed (%) | -5.05 | -0.46 | -4.72 | 16.10 | 5.12 | |
| Return on Assets (%) | -25.03 | 0.69 | -4.42 | -0.07 | 2.11 | |
| Total Debt/Equity (X) | 7.22 | 0.92 | 0.41 | 0.98 | 1.14 | |
| Asset Turnover Ratio (%) | 18.41 | 16.55 | 17.02 | 32.13 | 25.11 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.55 | 0.72 | 0.38 | 0.36 | 0.44 | |
| Quick Ratio (X) | 0.45 | 0.63 | 0.33 | 0.29 | 0.39 | |
| Inventory Turnover Ratio (X) | 7.14 | 6.93 | 5.71 | 8.43 | 8.22 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 164.46 | 160.06 | 168.85 | 191.81 | 244.21 | |
| EV/Net Operating Revenue (X) | 4.04 | 3.89 | 4.05 | 2.46 | 4.26 | |
| EV/EBITDA (X) | -265.51 | 44.50 | 122.79 | 8.17 | 12.73 | |
| MarketCap/Net Operating Revenue (X) | 0.90 | 1.67 | 3.10 | 1.54 | 3.03 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.95 | 0.70 | 1.33 | 1.63 | 2.76 | |
| Price/Net Operating Revenue | 0.90 | 1.67 | 3.10 | 1.54 | 3.03 | |
| Earnings Yield | -1.51 | 0.03 | -0.08 | 0.00 | 0.03 |
30.01.2026
Lyka Labs Consolidated December 2025 Net Sales at Rs 30.73 crore, down 9.08% Y-o-Y
30.01.2026
Lyka Labs Standalone December 2025 Net Sales at Rs 30.73 crore, down 6.66% Y-o-Y
19.11.2025
Lyka Labs Consolidated September 2025 Net Sales at Rs 36.66 crore, down 10.92% Y-o-Y
13.11.2025
Lyka Labs Standalone September 2025 Net Sales at Rs 32.97 crore, down 19.89% Y-o-Y
30.01.2026
Lyka Labs Consolidated December 2025 Net Sales at Rs 30.73 crore, down 9.08% Y-o-Y
30.01.2026
Lyka Labs Standalone December 2025 Net Sales at Rs 30.73 crore, down 6.66% Y-o-Y
19.11.2025
Lyka Labs Consolidated September 2025 Net Sales at Rs 36.66 crore, down 10.92% Y-o-Y
13.11.2025
Lyka Labs Standalone September 2025 Net Sales at Rs 32.97 crore, down 19.89% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth